Research progress of anti-gout small molecules targeting the NLRP3 inflammasome / 药学学报
Acta Pharmaceutica Sinica
;
(12): 543-553, 2024.
Artículo
en Chino
| WPRIM
| ID: wpr-1016618
ABSTRACT
Currently, clinically used drugs for the treatment of gout inflammation, such as colchicine, nonsteroidal anti-inflammatory drugs, and glucocorticoids, can only relieve the pain of joint inflammation and have severe hepatorenal toxicity and multiple organ adverse reactions. The NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome is a key complex that induces the onset of gout inflammation and has become a crucial target in the development of anti-gout drugs. This article reviews the research progress of anti-gout small molecules targeting the NLRP3 inflammasome and their bioactivity evaluation methods in the past five years, in order to provide information for the development of specific drugs for the treatment of gout inflammation.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Acta Pharmaceutica Sinica
Año:
2024
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS